The 503B bulks-list proposal: planning search for a product universe that can shrink
On 30 April 2026 FDA proposed to permanently exclude semaglutide, tirzepatide and liraglutide from the list of bulk drug substances that outsourcing facilities may compound under section 503B. If finalised, the proposal would narrow the compounded GLP-1 route further. As of this brief's date it is a proposal, not a final rule.
What is confirmed and what is not
Confirmed: the proposal and its date, as reported by Stanford Medicine and legal commentators; FDA's stated concern with adverse events associated with compounded semaglutide and tirzepatide (more than 1,700 logged as of 21 May 2026 per the same reporting). Not confirmed: whether, when and in what form the proposal is finalised. We will link the Federal Register docket at the next review and update this brief.
Why a marketer should care before it is final
Telehealth sites built around compounded-product availability carry pages, titles and comparison tables that become wrong the day the rule changes. In our category work this year we have watched a product cluster go from target keyword to frozen in a single week after litigation. The search plan has to assume the product universe can shrink.
How we plan for it
- Every compounded-product page carries a "changed" watch in our rule store and a review date.
- Programme, eligibility, cost and comparison pages are written so that the programme, not one compound, is the entity.
- A replacement revenue page is identified and built before it is needed.
- Redirect and rewrite plans exist for the pages most exposed, so a change costs a week, not a quarter of rankings.
Escalation
What your programme may offer, and under which pharmacy and prescribing arrangements, is a question for your counsel and pharmacy partners. This brief records the public proposal and our planning response.
Sources
- Stanford Medicine: Compounded GLP-1s, why doctors worry and the FDA is cracking down (summarises the April 2026 proposal and adverse-event counts) (2026-07) — https://med.stanford.edu/news/insights/2026/07/glp1s-compounded-why-doctors-worry-about-safety.html
- FDA human drug compounding: bulk drug substances — https://www.fda.gov/drugs/human-drug-compounding
GLP-1SEO provides search-marketing services and publishes search-marketing analysis. We are not physicians, pharmacists, lawyers or regulatory consultants, and nothing on this site is medical, legal or regulatory advice, or advice to patients. Clients remain responsible for obtaining qualified advice about their products, claims, jurisdictions and operations.